Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Abstract: Levulinic-capped estolides having improved physical properties that make them more desirable and suitable as bio-based industrial or commercial products are disclosed. The physical properties of the disclosed estolide compositions have surprisingly low pour points that are substantially lower than previously known estolide compounds and superior to petroleum-based compounds designed for similar applications.

Abstract: A method of interferometric optical sensing via spatial demodulation includes emitting a laser beam; splitting the laser beam into a reference beam and an interrogation beam; converting a desired signal into a change in the optical path of the interrogation beam via an optical sensor; and capturing the reference beam and the interrogation beam via a camera, wherein the interrogation beam is incident to the camera at a first angle and the reference beam is incident to the camera at a second angle different from the first angle, thereby causing an interference pattern at the camera.

Abstract: A graphene and liquid crystal device comprising a substrate, a layer of graphene on the substrate, and a layer of liquid crystal on the layer of graphene. A method of making a graphene and liquid crystal device comprising the steps of providing a substrate, depositing a layer of graphene on the substrate, and depositing a layer of liquid crystals on the layer of graphene.

Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Abstract: A process for producing metastable nanocrystalline alpha-alumina (?-Al2O3) having particle sizes smaller than 12 nm. Starting crystallites of ?-Al2O3 having a particle size larger than 12 nm, typically on the order of about 50 nm, are ball-milled at low temperatures to produce a nanocrystalline ?-Al2O3 powder having a particle size of less than 12 nm, i.e., below the theoretical room temperature thermodynamic size limit at which ?-Al2O3 changes phase to ?-Al2O3, wherein the powder remains in the ?-Al2O3 phase at all times.

Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.

Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

Abstract: Kinetic monitoring of in vivo metabolism of labelled tracers is based on singular value decomposition or Tucker Decomposition of magnetic resonance spectral image data. Data decomposition is used in conjunction with rank reduction to improve signal-to-noise ratio. Rank reduction can be applied in one or more of a spectral, spatial, or temporal dimension. Rank is generally reduced based on a number of expected analytes/metabolites or fit of measured data to a model.

Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.

Abstract: A method for autonomous systems comprising the steps of using a feedback circuit to provide power to an autonomous system, wherein the feedback circuit is configured to alternate between a first and second source of power depending on availability of power; creating a delay in the circuit by electrically coupling the circuit to a comparator, a one-shot signal, and a low pass filter, wherein the delay is configured to last for a specified amount of time, and wherein the delay will prevent the power from uncontrolled back and forth oscillation between the first and second power source.

Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Abstract: Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.

Abstract: Disclosed herein is a method and apparatus for forming pellets in a non-ambient environment such as a strong magnetic field. The apparatus includes a die body, a die bottom, a short push pin, a long push pin, a press tube, and an extended push pin. A powder is loaded into the die body, which is then positioned in the non-ambient environment, and the powder allowed to equilibrate. A pellet is then formed by pressing on the extended push pin while the powder is in the non-ambient environment.

Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.

Abstract: Variations in a translucent medium are imaged by detecting deflections and/or polarization shifts in a probe beam transmitted through the translucent medium. Deflections and polarization shifts may be detected using a first polarizing filter positioned between a probe beam generator and the translucent medium to polarize the probe beam in a first direction, a beam splitter positioned to receive the probe beam after it has been transmitted through the medium, and a probe beam deflection detector that receives a first split beam and provides a deflection signal associated with refractive index variations in the medium. A second polarizing filter receives a second split beam and polarizes it in a second direction, perpendicular to the first direction. An intensity sensor receives the second split beam, after it has passed through the second polarizing filter, and provides an intensity signal associated with a polarization shift in the medium.

Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula. The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.

Abstract: Resonant-cavity infrared photodetector (RCID) devices that include a thin absorber layer contained entirely within the resonant cavity. In some embodiments, the absorber is a single type-II InAs—GaSb interface situated between an AlSb/InAs superlattice n-type region and a p-type AlSb/GaSb region. In other embodiments, the absorber region comprises quantum wells formed on an upper surface of the n-type region. In other embodiments, the absorber region comprises a “W”-structured quantum well situated between two barrier layers, the “W”-structured quantum well comprising a hole quantum well sandwiched between two electron quantum wells. In other embodiments, the RCID includes a thin absorber region and an nBn or pBp active core within a resonant cavity. In some embodiments, the RCID is configured to absorb incident light propagating in the direction of the epitaxial growth of the RCID structure, while in other embodiments, it absorbs light propagating in the epitaxial plane of the structure.